Document is current

Article History

Accepted: 16 April 2024

First Online: 18 May 2024

Change Date: 10 August 2024

Change Type: Update

Change Details: In this article the below mentioned reference has been updated

Change Details: 10. Allecra Therapeutics. Allecra Therapeutics announces US FDA approval for EXBLIFEP® for the treatment of complicated urinary tract infections [media release]. 27 Feb 2024. HYPERLINK "

Change Details: https://www.allecra.com

Change Details: ".

Change Details: 12. ADVANZ PHARMA Limited, Allecra Therapeutics. ADVANZ PHARMA and Allecra Therapeutics announce approval in the European Union for the new antibiotic combination EXBLIFEP® (cefepime/enmetazobactam) for the treatment of severe infections [media release]. 27 Mar 2024.

Change Details: https://www.advanzpharma.com/

Change Details: .

Change Details: 14. Allecra Therapeutics. Allecra Therapeutics and ADVANZ PHARMA sign exclusive license and supply agreement for Allecra’s antibiotic cefepime/enmetazobactam in Europe [media release]. 13 Jan 2022. HYPERLINK "

Change Details: https://www.allecra.com/

Change Details: ".

Change Details: 15. Allecra Therapeutics GmbH, Shanghai Haini Pharmaceutical Co Ltd. Allecra Therapeutics and Shanghai Haini Pharmaceutical announce exclusive licensing agreement for cefepime/enmetazobactam for Greater China [media release]. 21 Dec 2020. HYPERLINK "

Change Details: https://www.allecra.com/

Change Details: ".

Change Details: 16. Orchid Chemicals & Pharmaceuticals. Orchid enters into strategic partnership with Allecra Therapeutics for development of novel antibiotics [media release]. 18 Apr 2013. HYPERLINK "

Change Details: https://www.orchidpharma.com/

Change Details: .

Declarations

:

: During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan J. Keam is a contracted employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.

: Not applicable.